Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

SYSTEMIC LUPUS ERYTHEMATOSUS IN THE ELDERLY

Identifieur interne : 002442 ( Main/Exploration ); précédent : 002441; suivant : 002443

SYSTEMIC LUPUS ERYTHEMATOSUS IN THE ELDERLY

Auteurs : Gary M. Kammer ; Nilamadhab Mishra

Source :

RBID : ISTEX:A52EC4391260D3DB7095D6F0169A1265B635AFE0

English descriptors

Abstract

Systemic lupus erythematosus (SLE) is an idiopathic autoimmune disorder that predominantly afflicts women in the childbearing years.44 SLE is acknowledged as a multigenic disease in which environmental factors are likely to modulate expression of susceptibility genes.40 In addition to the environment, evidence supports the concept that the geographic origin of populations and age affect the presentation and clinical course of SLE.8,10,33 Together, these factors contribute to the prevalence of SLE, which approximates 14.6 to 50.8 cases per 100,000 people in the United States. During the past two decades, epidemiologic analyses have revealed that SLE can present de novo in people in the sixth decade of life and older.85 Presentation and clinical course of the disease often differ from that observed in persons whose disease onset is in the second through fourth decades. An abnormal immune response involving both the cellular and humoral arms of the immune system has been well characterized in SLE, and continues to be the focus of intensive scrutiny.1 Whether the mechanisms underlying the abnormal immune response in younger-onset SLE are similar to or different from that in older-onset lupus remains largely unexplored. This article reviews recent information about the epidemiology, immune response, clinical presentation, laboratory findings, treatment, and prognosis in late-onset SLE. Because SLE has a higher incidence in younger and middle-aged adults and its clinical manifestations during these periods are more familiar, the clinical presentation and course of older and younger cohorts is compared whenever possible. Such a comparison will underscore the differences and the similarities of the clinical manifestations and will provide new insights and understanding of how age affects the clinical presentation of SLE.

Url:
DOI: 10.1016/S0889-857X(05)70152-6


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>SYSTEMIC LUPUS ERYTHEMATOSUS IN THE ELDERLY</title>
<author>
<name sortKey="Kammer, Gary M" sort="Kammer, Gary M" uniqKey="Kammer G" first="Gary M." last="Kammer">Gary M. Kammer</name>
</author>
<author>
<name sortKey="Mishra, Nilamadhab" sort="Mishra, Nilamadhab" uniqKey="Mishra N" first="Nilamadhab" last="Mishra">Nilamadhab Mishra</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A52EC4391260D3DB7095D6F0169A1265B635AFE0</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1016/S0889-857X(05)70152-6</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-K3Z9FV6R-D/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000176</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000176</idno>
<idno type="wicri:Area/Istex/Curation">000176</idno>
<idno type="wicri:Area/Istex/Checkpoint">001258</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001258</idno>
<idno type="wicri:doubleKey">0889-857X:2000:Kammer G:systemic:lupus:erythematosus</idno>
<idno type="wicri:Area/Main/Merge">002469</idno>
<idno type="wicri:Area/Main/Curation">002442</idno>
<idno type="wicri:Area/Main/Exploration">002442</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">SYSTEMIC LUPUS ERYTHEMATOSUS IN THE ELDERLY</title>
<author>
<name sortKey="Kammer, Gary M" sort="Kammer, Gary M" uniqKey="Kammer G" first="Gary M." last="Kammer">Gary M. Kammer</name>
</author>
<author>
<name sortKey="Mishra, Nilamadhab" sort="Mishra, Nilamadhab" uniqKey="Mishra N" first="Nilamadhab" last="Mishra">Nilamadhab Mishra</name>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Rheumatic Disease Clinics of North America</title>
<title level="j" type="abbrev">RDC</title>
<idno type="ISSN">0889-857X</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="2000">2000</date>
<biblScope unit="volume">26</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="475">475</biblScope>
<biblScope unit="page" to="492">492</biblScope>
</imprint>
<idno type="ISSN">0889-857X</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0889-857X</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Anticardiolipin antibodies</term>
<term>Antimalarial agents</term>
<term>Antinuclear antibody</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Autoantibody</term>
<term>Cell compartment</term>
<term>Cell immunol</term>
<term>Cell receptor</term>
<term>Cellular pathogenesis</term>
<term>Clin</term>
<term>Clinical features</term>
<term>Clinical presentation</term>
<term>Corticosteroid</term>
<term>Corticosteroid therapy</term>
<term>Current evidence</term>
<term>Cytokine</term>
<term>Cytokine production</term>
<term>Deficient type</term>
<term>Disease activity</term>
<term>Elderly donors</term>
<term>Elderly humans</term>
<term>Elderly subjects</term>
<term>Erythematosus</term>
<term>Herpes</term>
<term>Herpes zoster</term>
<term>Humana press</term>
<term>Hydroxychloroquine</term>
<term>Immune system</term>
<term>Immunol</term>
<term>Immunosuppressive therapy</term>
<term>Kammer</term>
<term>Kammer mishra</term>
<term>Kinase</term>
<term>Late onset</term>
<term>Lupus</term>
<term>Lupus erythematosus</term>
<term>Lupus nephritis</term>
<term>Mech ageing</term>
<term>Mishra</term>
<term>Nephritis</term>
<term>Other autoantibodies</term>
<term>Pathway</term>
<term>Peripheral blood</term>
<term>Protein kinase</term>
<term>Rash</term>
<term>Receptor</term>
<term>Rheum</term>
<term>Rheumatol</term>
<term>Rheumatology</term>
<term>Senescent</term>
<term>Signal transduction</term>
<term>Syndrome</term>
<term>Systemic</term>
<term>Systemic lupus erythematosus</term>
<term>Whisler</term>
<term>Zoster</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Systemic lupus erythematosus (SLE) is an idiopathic autoimmune disorder that predominantly afflicts women in the childbearing years.44 SLE is acknowledged as a multigenic disease in which environmental factors are likely to modulate expression of susceptibility genes.40 In addition to the environment, evidence supports the concept that the geographic origin of populations and age affect the presentation and clinical course of SLE.8,10,33 Together, these factors contribute to the prevalence of SLE, which approximates 14.6 to 50.8 cases per 100,000 people in the United States. During the past two decades, epidemiologic analyses have revealed that SLE can present de novo in people in the sixth decade of life and older.85 Presentation and clinical course of the disease often differ from that observed in persons whose disease onset is in the second through fourth decades. An abnormal immune response involving both the cellular and humoral arms of the immune system has been well characterized in SLE, and continues to be the focus of intensive scrutiny.1 Whether the mechanisms underlying the abnormal immune response in younger-onset SLE are similar to or different from that in older-onset lupus remains largely unexplored. This article reviews recent information about the epidemiology, immune response, clinical presentation, laboratory findings, treatment, and prognosis in late-onset SLE. Because SLE has a higher incidence in younger and middle-aged adults and its clinical manifestations during these periods are more familiar, the clinical presentation and course of older and younger cohorts is compared whenever possible. Such a comparison will underscore the differences and the similarities of the clinical manifestations and will provide new insights and understanding of how age affects the clinical presentation of SLE.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Kammer, Gary M" sort="Kammer, Gary M" uniqKey="Kammer G" first="Gary M." last="Kammer">Gary M. Kammer</name>
<name sortKey="Mishra, Nilamadhab" sort="Mishra, Nilamadhab" uniqKey="Mishra N" first="Nilamadhab" last="Mishra">Nilamadhab Mishra</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002442 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002442 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A52EC4391260D3DB7095D6F0169A1265B635AFE0
   |texte=   SYSTEMIC LUPUS ERYTHEMATOSUS IN THE ELDERLY
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021